The significance of alterations in mediator kinase components and cancer progression has spurned the development of specific CDK8/19 inhibitors (28, –, 30), several of which are in clinical trials for ER-positive breast cancers and acute myeloid leukemia (31). The gene discussed is CDK8; the disease is cancer.